CompletedNot Applicable

Cytological Examination of Malignant Pleural Effusion in Breast Cancer

Egypt50 participantsStarted 2024-10-19

Plain-language summary

Malignant pleural effusion (MPE) is characterized by the presence of malignant cells. It can occur in 15% of patients with cancer and is a common manifestation in patients with metastatic disease. Breast cancer (BC) is the second most common cause of MPE and MPE occurring in 2- 11% of patients with BC. Breast cancer is a heterogeneous disease of malignant tumors with diversified morphology, clinical course, biologic behavior and prognosis, and accurate tumor classification is critical for a patient's care.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients will be included if they are presented for thoracentesis with routine cytological examination of pleural effusion before biopsy or thoracoscopy, if the appearance of visceral and parietal pleural was clearly and if malignant diagnosis of breast was confirmed on histological analysis of the biopsy material. Exclusion Criteria: * Age \<18 years. * Patients diagnosed with malignant pleural mesothelioma (MPM) * Contraindication for pleurocentesis; patient refusing, coagulopathy and active skin infection

What they're measuring

Cytological examination of pleural effusion in breast cancer ( cell/unit)

Timeframe: 6 months

Trial details

NCT IDNCT06657638

SponsorMansoura University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-19

View on ClinicalTrials.gov More Malignant Pleural Effusion trials